一、2025 年限制性股票激励计划预留授予分配情况 北京阳光诺和药物研究股份有限公司 2025 年限制性股票激励计划预留授予激励对象名单 （截至预留授予日） 3. 上表中数值若出现总数与各分项数值之和尾数不符，均为四舍五入原因所致。 特此公告 北京阳光诺和药物研究股份有限公司董事会 2025 年 10 月 29 日 1 本激励计划首次授予的限制性股票在各激励对象间的分配情况如下表所示： | 姓名 | 国籍 | 职务 | 获授限制性 | 占授予限制 | 占本激励计 划公告时股 | | | --- | --- | --- | --- | --- | --- | --- | | | | | 股票数量 （万股） | 性股票总数 的比例 | 本总额的比 例 | | | 一、董事、高级管理人员、核心技术人员 | | | | | | | | / | / | / | / | / | | / | | 小计 | | | / | / | | / | | 二、其他激励对象 | | | | | | | | 董事会认为需要激励的人员（13 | | 人） | 54.4355 | 20% | 0.49% | | | 合计 | | | 54. ...

北京市天元律师事务所 关于北京阳光诺和药物研究股份有限公司 2025 年限制性股票激 励计划预留授予事项的 法律意见 京天股字（2025）第 153-4 号 致：北京阳光诺和药物研究股份有限公司 北京市天元律师事务所（以下简称本所）接受北京阳光诺和药物研究股份有 限公司（以下简称公司或阳光诺和）的委托，担任公司 2025 年限制性股票激励 计划（以下简称本激励计划）的专项中国法律顾问并出具法律意见。 本所及经办律师依据《中华人民共和国公司法》（以下简称《公司法》）、《中 华人民共和国证券法》（以下简称《证券法》）、《律师事务所从事证券法律业务管 理办法》《上市公司股权激励管理办法》（以下简称《管理办法》）、《上海证券交 易所科创板股票上市规则》《科创板上市公司自律监管指南第 4 号——股权激励 信息披露》等法律、法规和中国证券监督管理委员会（以下简称中国证监会）的 有关规定及本法律意见出具日以前已经发生或者存在的事实，按照律师行业公认 的业务标准、道德规范和勤勉尽责的精神，出具本法律意见。 北京市天元律师事务所 关于北京阳光诺和药物研究股份有限公司 2025 年限制性股票激励计划预留授予事项的 法律意见 北京 ...

证券代码：688621 证券简称：阳光诺和 公告编号：2025-087 1. 原股东会的类型和届次： 2025年第四次临时股东会 | 股份类别 | 股票代码 | 股票简称 | 股权登记日 | | --- | --- | --- | --- | | 股 A | 688621 | 阳光诺和 | 2025/10/17 | 二、 股东会延期原因 北京阳光诺和药物研究股份有限公司 关于2025年第四次临时股东会再次延期的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议延期后的召开时间：2025 年 11 月 11 日 一、 原股东会有关情况 鉴于相关工作统筹安排需要，经审慎研究，为确保本次股东会顺利召开，公 司决定将原定于 2025 年 10 月 30 日（星期四）召开的 2025 年第四次临时股东会 再次延期至 2025 年 11 月 11 日（星期二）举行。除会议召开日期调整外，本次 股东会的股权登记日及审议事项等其他安排均保持不变。 本次临时股东会的延期符合《上市公司股东会规则》和《上海证券交易所股 票 ...

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry [1] Core Insights - The report highlights significant advancements in innovative drugs, particularly in the context of recent clinical trial results presented at the 2025 ESMO conference, showcasing the potential for new treatment options in various cancer types [12][19] - The report emphasizes the emergence of domestic drugs that have achieved notable efficacy in treating conditions such as NSCLC and HER2-positive breast cancer, indicating a shift in the competitive landscape [13][17] Summary by Sections 1. New Drug Developments - **2L EGFR Mutant NSCLC**: The drug Lukanosumab (sac-TMT) is the first to demonstrate both overall survival (OS) and progression-free survival (PFS) benefits in patients with TKI-resistant NSCLC, with mPFS of 8.3 months compared to 4.3 months for chemotherapy [13][14] - **HER2 Positive Breast Cancer**: The drug Ruikang Trastuzumab shows longer mPFS of 30.6 months compared to 8.3 months for the chemotherapy combination, indicating a promising new option for patients [17][18] - **T-Bren for Breast Cancer**: Early data from the T-Bren trial shows a clinical overall response rate (cORR) of 82.2% in HER2-positive patients, with mPFS of 18.0 months [19][20] - **2L HER2 Positive Gastric Cancer**: Anniotuzumab combined with chemotherapy shows significant improvements in mPFS (7.1 months vs 2.7 months) and mOS (19.6 months vs 11.5 months), suggesting a potential shift in treatment paradigms [21][24] 2. Market Performance - The pharmaceutical and biotechnology sector saw a 0.58% increase in October, underperforming the CSI 300 index by 2.67 percentage points, ranking 25th among 31 sub-industries [25][30] - The medical research outsourcing sector experienced the highest growth, up 5.47%, while other bioproduct sectors faced declines [30][34]

Core Viewpoint - Sunshine Nuohuo's stock price has experienced fluctuations, with a year-to-date increase of 57.19% but a recent decline of 24.83% over the past 20 days [1][2]. Financial Performance - For the first half of 2025, Sunshine Nuohuo reported revenue of 590 million yuan, representing a year-on-year growth of 4.87%. However, the net profit attributable to shareholders decreased by 12.61% to 130 million yuan [2]. - Cumulative cash dividends since the company's A-share listing amount to 105 million yuan, with 84.29 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders increased by 18.76% to 8,621, while the average circulating shares per person decreased by 15.80% to 12,991 shares [2]. - Among the top ten circulating shareholders, notable changes include a decrease in holdings for both Rongtong Health Industry Flexible Allocation Mixed A/B and Anxin Medical Health Stock A [3]. Company Overview - Sunshine Nuohuo, established on March 9, 2009, and listed on June 21, 2021, is based in Beijing and specializes in generic drug development, consistency evaluation, and innovative drug development [1]. - The company's main business revenue is derived from CRO services, accounting for 99.91% of total revenue, with other services contributing 0.09% [1].

Core Viewpoint - The investment by Sunshine Nuohong in Yuanma Zhiyao highlights the growing interest and potential in the in vivo CAR-T therapy sector, which is gaining traction among both multinational and domestic pharmaceutical companies [1][2][5]. Company Investment - Sunshine Nuohong announced an investment of 15 million yuan (approximately 2.1 million USD) in Yuanma Zhiyao, acquiring an 8.2% stake in the company [2][3]. - Yuanma Zhiyao, established in June 2023, focuses on the innovative development of circular mRNA in vivo CAR-T therapies and is currently in the early research phase [2][4]. Industry Trends - The in vivo CAR-T therapy market is experiencing increased investment and collaboration, with major pharmaceutical companies like AstraZeneca, AbbVie, and BMS making significant moves in this area [5][7]. - The traditional CAR-T therapy process is lengthy and costly, often taking 3-4 weeks and exceeding 1 million yuan (approximately 140,000 USD) in treatment costs, which limits its accessibility [3][7]. Technological Advantages - In vivo CAR-T therapy offers a streamlined process, potentially reducing preparation time to 2-3 days and costs to as low as 50,000 USD per treatment, making it more accessible for patients [7][10]. - The technology allows for the direct generation and activation of CAR-T cells within the patient, simplifying the treatment process and reducing the need for complex manufacturing [3][8]. Challenges and Future Outlook - Despite its potential, in vivo CAR-T therapy faces challenges such as delivery efficiency, dosage control, and long-term safety, which require further clinical validation [9][10]. - Industry experts predict that within 3-5 years, the first in vivo CAR-T product may receive approval, marking a significant advancement in cell therapy [10][11].

Group 1 - The fourth extraordinary general meeting of shareholders originally scheduled for October 23, 2025, has been postponed to October 30, 2025 [2][3] - The postponement is due to the ongoing approval process by the state-owned enterprise involved in the transaction, ensuring the smooth execution of the deal and protecting shareholders' rights [2] - Other arrangements, including the equity registration date and agenda items for the meeting, remain unchanged [2][4] Group 2 - The postponed meeting will take place at 14:30 on October 30, 2025, with online voting available on the same day [3] - The network voting period will be from 9:15 to 15:00 on the day of the meeting, with specific time slots for trading system voting [3] - Shareholders or their agents are responsible for their own travel and accommodation expenses when attending the meeting [5]

Core Viewpoint - The investment by Sunshine Nuohong in Yuanma Zhiyao highlights the growing interest and activity in the in vivo CAR-T therapy sector, which is seen as a promising alternative to traditional CAR-T therapies due to its potential for reduced costs and shorter preparation times [1][4][10]. Company Investment - On October 20, Sunshine Nuohong announced an investment of 15 million yuan (approximately 2.1 million USD) in Yuanma Zhiyao, acquiring an 8.2% stake in the company [4][5]. - Yuanma Zhiyao, established in June 2023, focuses on the innovative research and development of circular mRNA in vivo CAR-T therapies and is currently in the early stages of pipeline development [4][5]. Industry Trends - The in vivo CAR-T therapy field has seen increased investment and collaboration from major pharmaceutical companies, including AstraZeneca, AbbVie, and Bristol-Myers Squibb, indicating a trend towards this innovative treatment approach [8][9]. - The traditional CAR-T therapy process is lengthy and costly, typically taking 3-4 weeks and costing over 1 million yuan (approximately 140,000 USD), which limits its accessibility [5][10]. Advantages of In Vivo CAR-T - In vivo CAR-T therapy offers significant advantages over traditional methods, including a reduced preparation time of 2-3 days and potential cost reductions to below 50,000 USD per treatment [10][12]. - The technology allows for a more streamlined process, eliminating the need for personalized quality control and GMP cell factories, thus making it more accessible to patients [10][12]. Challenges Ahead - Despite its potential, in vivo CAR-T therapy faces challenges such as delivery efficiency, dosage control, and long-term safety, which require further clinical validation [11][12]. - The complexity of the human body poses risks in ensuring that the viral or LNP carriers deliver the intended effects without adverse reactions [11][12]. Future Outlook - Industry experts predict that within 3-5 years, the first in vivo CAR-T product may receive approval, potentially coexisting with traditional CAR-T therapies and becoming a mainstream treatment option [12][13]. - The ongoing advancements in research and clinical trials are expected to address current challenges, making in vivo CAR-T therapies more accessible and affordable for patients in the near future [13].

证券代码：688621 证券简称：阳光诺和 公告编号：2025-086 北京阳光诺和药物研究股份有限公司 关于2025年第四次临时股东会的延期公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 北京阳光诺和药物研究股份有限公司（以下简称"公司"）于 2025 年 9 月 25 日召开第二届董事会第二十三次会议，审议通过了《关于<北京阳光诺和药物研 究股份有限公司发行股份及可转换公司债券购买资产并募集配套资金暨关联交 易报告书（草案）>及其摘要的议案》《关于召开公司 2025 年度第四次临时股东 会的议案》等议案。 因目前国资交易对方仍在履行其所属国家出资企业的批准流程，为确保本次 1 2. 原股东会召开日期：2025 年 10 月 23 日 3. 原股东会股权登记日： 交易的顺利进行，充分保障全体股东的合法权益，经公司慎重研究，决定将 2025 年第四次临时股东会的召开日期由原定的 2025 年 10 月 23 日延期至 2025 年 10 月 30 日。除召开日期变更外，本次股东会的股权登记日及审议事项等 ...

Group 1 - Yonghe Co., Ltd. reported a net profit of 469 million yuan for the first three quarters, a year-on-year increase of 220.39% [1] - Jinli Permanent Magnet achieved a net profit of 515 million yuan, reflecting a year-on-year growth of 161.81% [1][2] - Sanhe Pharmaceutical Auxiliary's net profit increased by 8.28% year-on-year, reaching 133 million yuan [2] Group 2 - Jiahuan Technology experienced a net profit decline of 26.53%, totaling 55.35 million yuan [3] - Wuchan Huaneng reported a net profit decrease of 15.10%, amounting to 453 million yuan [3] - Chuan Investment Energy's net profit fell by 4.54%, totaling 4.22 billion yuan [4][5] Group 3 - Dayang Bio's net profit grew by 56.12%, reaching 80 million yuan [5] - Weili Medical reported a net profit increase of 14.94%, totaling 192 million yuan [6] - People's Tongtai's net profit decreased by 45.69%, amounting to 112 million yuan [7] Group 4 - Jiuhuan Bio received a medical device registration certificate for its NT-proBNP test kit [8] - Jincheng Pharmaceutical's subsidiary obtained a drug registration certificate for a specific injection [9] - Guangdian Yuntong's subsidiary acquired a money service operator license in Hong Kong [10] Group 5 - Dash Intelligent won a bid for a project worth 96 million yuan related to the Shijiazhuang subway [10] - Alloy Investment's net profit increased by 124.87%, reaching 7.26 million yuan [11] - Kaile Co., Ltd. reported a net profit growth of 159.14%, totaling 21.63 million yuan [12] Group 6 - Chuanjinno's net profit surged by 175.61%, reaching 304 million yuan [14] - Rijiu Optoelectronics reported a net profit increase of 36.54%, totaling 76.91 million yuan [15] - Dazhu CNC's net profit grew by 142.19%, amounting to 492 million yuan [15] Group 7 - Nairui Radar expects a net profit increase of 181% for the first three quarters [17] - Suzhou Tianmai successfully acquired land use rights for a new manufacturing project [19] - Aokai Pharmaceutical announced clinical research data for its innovative drug at a major conference [21][22] Group 8 - Jilin Aodong's subsidiary passed the consistency evaluation for a specific injection [24] - Qinxin Environment announced the resignation of a board member [25] - *ST Baoying is planning a change in control, leading to a stock suspension [26] Group 9 - Jianlang Hardware's director plans to reduce holdings by up to 500,000 shares [27] - Taihe Technology's director intends to reduce holdings by up to 606,000 shares [29] - Zhongyuan Securities announced a cash dividend of 0.008 yuan per share [31] Group 10 - Beijing-Shanghai High-Speed Railway plans to distribute a cash dividend of 0.0385 yuan per share [32] - Zhuhai Guanyu expects a net profit increase of 36.88%-55.54% for the first three quarters [34] - Shenglong Co., Ltd. reported a net loss of 72.95 million yuan for the first three quarters [36] Group 11 - Shuangyuan Technology plans to distribute a cash dividend of 0.125 yuan per share [38] - Shaanxi Guotou A reported a net profit increase of 6.6%, totaling 996 million yuan [40] - Sunshine Nuohua intends to invest 15 million yuan in a biotech company [41] Group 12 - Yangjie Technology's net profit increased by 45.51%, reaching 974 million yuan [42] - Xingwang Yuda reported a net profit growth of 260%, totaling 38.37 million yuan [43] - Tongyou Technology turned a profit with a net profit of 9.29 million yuan [44]